USE OF ANTITHYMOCYTE GLOBULIN (DOSE BY ROSETTE PROTOCOL) IN PEDIATRIC RENAL ALLOGRAFT RECIPIENTS
- 1 October 1979
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 28 (4) , 291-293
- https://doi.org/10.1097/00007890-197910000-00005
Abstract
Total rosette-forming cells (TRFCs) and percentage of rosette-forming cell (RFC) levels were measured in patients undergoing dialysis and in recipients following renal transplantation. The percentage of RFCs of the dialysis patients was not different from the percentage of RFCs of normal subjects, whereas the TRFCs were significantly lower in the dialysis patients. After transplantation, the percentage of RFCs and TRFCs was significantly lower in recipients treated with anti-thymocyte globulin (ATG) than in those of the control group; however, there was no difference in allograft survival between the ATG-treated and control recipients when using ATG in the dose by rosette protocol.This publication has 5 references indexed in Scilit:
- EFFECT OF ANTILYPHOCYTE-GLOBULIN POTENCY ON SURVIVAL OF CADAVER RENAL TRANSPLANTSThe Lancet, 1977
- The effect of uremia and transplantation on lymphocyte subpopulationsKidney International, 1976
- CANADIAN CLINICAL-TRIAL OF ANTILYMPHOCYTE GLOBULIN IN HUMAN CADAVER RENAL-TRANSPLANTATION1976
- T-rosettes in hemodialysis patients and renal allograft recipientsCellular Immunology, 1975
- USE OF HETEROLOGOUS ANTILYMPHOID AGENTS IN CANINE RENAL AND LIVER HOMOTRANSPLANTATION AND IN HUMAN RENAL HOMOTRANSPLANTATION1967